AbbVie says FDA approves SKYRIZI
AbbVie announced that the U.S. Food and Drug Administration approved SKYRIZI, an interleukin-23 inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, SKYRIZI produced high rates of durable skin clearance - most people treated with SKYRIZI achieved 90% skin clearance at one year, with the majority achieving complete skin clearance. "The complex nature of psoriasis and the variability or loss of treatment response over time can prevent some patients from achieving their treatment goals," said Kenneth B. Gordon, M.D., a principal investigator for the ultIMMa-1 pivotal trial and professor and chair of dermatology at the Medical College of Wisconsin. "In clinical trials, risankizumab demonstrated high levels of skin clearance that persisted through one year. I'm pleased the dermatology community now has a new option that can help patients achieve and maintain a high level of treatment response." SKYRIZI is expected to be available in the U.S. in early May.